Pompe disease drug receives FDA approval

On April 28, 2006, the U.S. Food and Drug Administration (FDA) granted marketing approval for the drug Myozyme (alglucosidase alfa) for treatment of Pompe disease in the United States. Manufactured by Genzyme Corp., Myozyme will be used for long-term enzyme replacement therapy in Pompe disease and is the first treatment ever approved for the disorder. On April 3, Myozyme received EMEA approval for marketing in the European Union.